Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).

Adams RA.; Fisher D.; Farragher S.; Scott A.; Smith CG.; James MD.; Cheadle J.; Nichols LL.; Meade AM.; Kaplan RS.; Wilson RH.; Wasan HS.; Maughan T.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue
Find out more

Site Map
Cookies
Log in
Contact us
Intranet
Accessibility

Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).

Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).

Adams RA., Fisher D., Farragher S., Scott A., Smith CG., James MD., Cheadle J., Nichols LL., Meade AM., Kaplan RS., Wilson RH., Wasan HS., Maughan T.

Type

Publication Date

Volume